| Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint Inhibitor Therapy (NCT07663422) | Fox Chase Cancer Center | 2026-06-30 |
| Prehabilitation in High-risk Oncologic Surgery (NCT07638410) | Fox Chase Cancer Center | 2026-06-15 |
| Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas (NCT07455032) | Fox Chase Cancer Center | 2026-04-08 |
| Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma (NCT07221942) | Fox Chase Cancer Center | 2026-01-23 |
| Adaptive Radiation Boost for Rectal Cancer (NCT07221058) | Fox Chase Cancer Center | 2025-10-24 |
| Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer (NCT07219303) | Fox Chase Cancer Center | 2025-09-25 |
| Adaptive Radiation for Locally Advanced Unresectable Pancreatic Cancer (NCT06984562) | Fox Chase Cancer Center | 2025-08-20 |
| Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma (NCT07043972) | Fox Chase Cancer Center | 2025-07-09 |
| MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma (NCT06557330) | Fox Chase Cancer Center | 2025-06-01 |
| Testing Gene PilotLX With Latinx Cancer Patients (NCT06476938) | Fox Chase Cancer Center | 2025-05-30 |
| Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for Chemotherapy-induced Peripheral Neuropathy. (NCT06914557) | Fox Chase Cancer Center | 2025-03-03 |
| Understanding the Preferences and Views of Older Adults on the Use of Geriatric and Objective Functional Assessments for Cancer Treatment Planning. (NCT06652347) | Fox Chase Cancer Center | 2025-02-21 |
| Communication About Sexual Health in Gynecologic Cancer (NCT06904339) | Fox Chase Cancer Center | 2025-02-20 |
| Reducing Urban Cervical Cancer Disparities (NCT06416150) | Fox Chase Cancer Center | 2024-08-28 |
| Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) (NCT06396533) | Fox Chase Cancer Center | 2024-08-13 |
| Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition (NCT06218628) | Fox Chase Cancer Center | 2024-04-05 |
| HPV Self-sampling for Underscreened Latinas (NCT06439706) | Fox Chase Cancer Center | 2023-10-04 |
| A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA) (NCT06050954) | Fox Chase Cancer Center | 2023-09-01 |
| Adaptive Radiation for Abdominopelvic Metastases (NCT05880667) | Fox Chase Cancer Center | 2023-08-01 |
| Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma (NCT05923190) | Fox Chase Cancer Center | 2023-06-14 |
| mychoiceTM Implementation With Medical Oncology Patients (NCT06222242) | Fox Chase Cancer Center | 2023-06-07 |
| Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET (NCT05420636) | Fox Chase Cancer Center | 2022-12-21 |
| Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in Melanoma (NCT05498792) | Fox Chase Cancer Center | 2022-11-30 |
| African Cancer Genome: GMD (NCT05754658) | Fox Chase Cancer Center | 2022-11-28 |
| Feasibility, Acceptability and Fidelity of Integrating a Navigation Intervention Into Tobacco Treatment Program (NCT07072312) | Fox Chase Cancer Center | 2022-11-10 |
| Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major Cancer Operations (PRS II) (NCT05454280) | Fox Chase Cancer Center | 2022-10-14 |
| Buprenorphine for Cancer Pain (NCT05910190) | Fox Chase Cancer Center | 2022-08-10 |
| Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC (NCT05400577) | Fox Chase Cancer Center | 2022-07-13 |
| Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients (NCT05274048) | Fox Chase Cancer Center | 2022-06-24 |
| Women's Health Communication Study (NCT05359952) | Fox Chase Cancer Center | 2022-02-09 |
| Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors (NCT05263050) | Fox Chase Cancer Center | 2022-01-21 |
| A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to Patients With Advanced Cancer (NCT04827810) | Fox Chase Cancer Center | 2021-11-05 |
| Local Consolidative Therapy in Colorectal Cancer (NCT05062720) | Fox Chase Cancer Center | 2021-07-29 |
| HM-178: Assessing Methods for Improvement in Methotrexate Toxicity Management and Detection of Central Nervous System Involvement of Aggressive Lymphoma (NCT04668768) | Fox Chase Cancer Center | 2021-04-16 |
| Evidence-Based Approach to Empower Asian American Women in Cervical Cancer Screening (NCT04557423) | Fox Chase Cancer Center | 2021-04-08 |
| Couples' QOL in Metastatic Breast Cancer (NCT05636943) | Fox Chase Cancer Center | 2021-01-01 |
| A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer (NCT04506554) | Fox Chase Cancer Center | 2020-12-01 |
| Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC (NCT03527108) | Fox Chase Cancer Center | 2020-10-08 |
| Improving the Approach to and Management of the Older Patient With Metastatic Gastric Cancer (NCT04618809) | Fox Chase Cancer Center | 2020-09-22 |
| Phase I Study in Advanced Malignancies With 5-ALA (NCT04381806) | Fox Chase Cancer Center | 2020-07-30 |
| nCLE For Diagnosis Of Peripheral Lung Nodules By Robotic Navigational Bronchoscopy (NCT04441749) | Fox Chase Cancer Center | 2020-06-29 |
| Efficacy of Topical Mitomycin C for Complex Benign Esophageal Anastomotic Strictures (NCT04037072) | Fox Chase Cancer Center | 2020-04-03 |
| Liver Cancer Community Education (NCT04272619) | Fox Chase Cancer Center | 2020-02-11 |
| Clinician Communication About Sexual Health (NCT04262219) | Fox Chase Cancer Center | 2020-02-07 |
| Pulse-low-dose Rate (PLDR) Radiation in Pancreatic Cancer (NCT04452357) | Fox Chase Cancer Center | 2020-01-13 |
| Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLC (NCT03786692) | Fox Chase Cancer Center | 2019-09-04 |
| Coping Together After Breast Cancer (NCT03930797) | Fox Chase Cancer Center | 2019-05-24 |
| Utility of CAML as Diagnostic for Early Stage Lung Cancer (NCT03992183) | Fox Chase Cancer Center | 2019-05-21 |
| Palliative and Oncology Care Intervention: Symptom COACH (NCT03760471) | Fox Chase Cancer Center | 2018-11-07 |
| Atorvastatin ± Aspirin in Lynch Syndrome Syndrome (NCT04379999) | Fox Chase Cancer Center | 2018-09-10 |
| A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma (NCT03310567) | Fox Chase Cancer Center | 2018-09-01 |
| Mychoice: Testing an Interactive mHealth Tool (NCT03427177) | Fox Chase Cancer Center | 2018-06-25 |
| Addressing Sexual Concerns in Breast Cancer: Patient Intervention Study (NCT03624972) | Fox Chase Cancer Center | 2018-05-27 |
| Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance (NCT03311958) | Fox Chase Cancer Center | 2018-05-15 |
| Pilot Study to Investigate The Diagnostic Yield and Utility of 22g and 19g Endobronchial Ultrasound Transbronchial Needle Aspirate (NCT03311620) | Fox Chase Cancer Center | 2018-05-15 |
| Organ Preservation in Early Rectal Cancer Patients (NCT03548961) | Fox Chase Cancer Center | 2018-05-11 |
| Impact of Ribociclib on Head and Neck Squamous Cell Cancer (NCT03179956) | Fox Chase Cancer Center | 2018-04-02 |
| Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy (NCT03302247) | Fox Chase Cancer Center | 2018-01-15 |
| Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma (NCT03291028) | Fox Chase Cancer Center | 2017-11-27 |
| Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma (NCT03179943) | Fox Chase Cancer Center | 2017-11-27 |
| Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC (NCT03099486) | Fox Chase Cancer Center | 2017-10-06 |